Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Synairgen Completes Recruitment of Hospitalised Patients in COVID-19 Trial | ||
By: GlobeNewswire - 28 May 2020 | Back to overview list |
|
Press release Synairgen plc Synairgen Completes Recruitment of Hospitalised Patients in COVID-19 Trial Southampton, UK – 28 May 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, is pleased to announce that recruitment of 100 hospitalised patients in its clinical trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients has now been completed. The COVID-19 study Richard Marsden, CEO of Synairgen, commented: “We are pleased to have now completed recruitment in this important study, with initial trial data expected in July 2020. A successful outcome from this trial could be a critical step towards strengthening the fight against the COVID-19 pandemic.” For further enquiries, please contact: Synairgen plc finnCap Consilium Strategic Communications (Financial Media and Investor Notes for Editors About Synairgen Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com COVID-19 Interferon beta (IFN-beta) potential applicability to COVID-19 Two Phase II clinical trials in asthma showed that inhaled SNG001 treatment activated antiviral pathways in the lung along with improving lung function in patients with a respiratory viral infection. We have also shown that treatment with inhaled SNG001 reduced lung viral load and lung pathology in an in vivo swine flu driven model of viral pneumonia. At the time of the MERS-CoV outbreak in 2013, Synairgen collaborated with the National Institutes of Health (NIH) in the US to show that SNG001 could protect against MERS-CoV infection of lung cells in vitro. |
||
|
||
Copyright 2020 GlobeNewswire | Back to overview list |